Tellgen

Tellgen, based on independent innovation, has built multiple technological platforms including high-throughput flow fluorescence hybridization technology platform, high-throughput flow immunofluorescence technology platform, multiplex fluorescence PCR technology platform, and chemiluminescence immunoassay technology platform. These platforms complement each other and have their own strengths: the high-throughput flow fluorescence technology platform is characterized by the ability to detect multiple indicators at once, high parallel detection throughput, and fast detection speed, which can be widely used in the development of multi-index joint detection products; the chemiluminescence technology platform has the advantages of high sensitivity, strong specificity, wide linear range, and high degree of automation, suitable for the development of single-index immune diagnostic products; the multiplex fluorescence PCR platform is mainly used for the development of molecular products. Meanwhile, Tellgen launched the "Hitachi-Tellgen Compatible Assembly Line" in 2018, realizing full laboratory automation. Tellgen has introduced a series of innovative products in many fields such as cancer detection, cervical cancer screening, DNA methylation detection, male infertility, and eugenics, becoming a company with comprehensive testing items and advanced technology in the field of tumor markers and HPV detection in China and even internationally. Tellgen Technology has obtained more than 50 medical device registration certificates cumulatively, with products covering tumor markers, cervical cancer screening, lung cancer DNA methylation, male infertility, gene mutation detection, eugenics, and tumor quality control products.